<a href="https://laohu8.com/S/VSTM">Verastem</a> Reports 41% Response Rate in Phase 1/2 Trial of KRAS G12D Inhibitor for Advanced Pancreatic Cancer
Verastem Oncology has announced updated efficacy and safety results from GenFleet Therapeutics' Phase 1/2 monotherapy study of GFH375 (VS-7375 outside China), an oral KRAS G12D inhibitor, in patients with advanced KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC). The data were presented as a late-breaking abstract at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Among 59 efficacy-evaluable, heavily pre-treated patients receiving 600 mg daily, the overall response rate was 40.7%, and the disease control rate was 96.7%. At month four, the observed overall survival rate was 92.2%, with median overall survival not reached as of the data cutoff. The median progression-free survival was 5.52 months. The study reported a manageable safety profile, with a 4% discontinuation rate due to adverse events. At the time of evaluation, 47% of patients remained on treatment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-100537), on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.